You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.
PATIENT SUPPORT SERVICES
Jazz is committed to removing barriers to access and reimbursement
JazzCares® provides assistance to patients and practices with:
Understanding existing insurance coverage, PA and appeals support,a billing and coding, referrals to other financial assistance
Free drug program for eligible patients: Uninsured or underinsured patients who meet certain financial criteria may be eligible to receive Defitelio at no costb
For more information
- Call the Patient Support Hotline at 1-833-533-JAZZ (5299), Monday - Friday, 8:00 AM - 8:00 PM ET
- To contact your Jazz Access and Reimbursement Manager, visit www.jazzcares.com/contact-arm/
aInsurance coverage and plans may vary. JazzCares program provides general information only and is not a guarantee of any coverage or reimbursement outcome. All treatment decisions rest solely with the treating physician or qualified healthcare professional.
bSubject to financial and residency eligibility criteria. Terms and conditions apply.
For additional information call Jazz Pharmaceuticals Customer Service
Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
IMPORTANT SAFETY INFORMATION
Defitelio is contraindicated in the following conditions:
- Concomitant administration with systemic anticoagulant or fibrinolytic therapy
- Known hypersensitivity to Defitelio or to any of its excipients
Warnings and Precautions
Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.
Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.
Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.Please see full Prescribing Information.